Granulomatose avec polyangéite : quoi de neuf ? [Granulomatosis with polyangiitis: what's new?]

Détails

Ressource 1Demande d'une copie Sous embargo jusqu'au 05/10/2024.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_D369BEFFD011
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Granulomatose avec polyangéite : quoi de neuf ? [Granulomatosis with polyangiitis: what's new?]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Ringwald M., Chevalley D., Bongard C., Kissling S., Rotman S., Von Garnier C., Ribi C., Comte D.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
05/04/2023
Peer-reviewed
Oui
Volume
19
Numéro
821
Pages
674-679
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
Within the group of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides, granulomatosis with polyangiitis (GPA) is the most frequent. The incidence is around 10 to 20 cases/million/year. Clinical manifestations are varied, with ENT, lungs and kidneys most frequently involved. ANCA are pathogenic by triggering neutrophil activation, which leads to vascular damage. Detection of ANCA is most helpful in establishing the diagnosis, but serology may be negative in GPA limited to the airways. Diagnostic work-up and therapy require a multidisciplinary approach. Treatment includes an induction and maintenance phase, combining corticosteroids and immunosuppressive drugs. It aims at limiting the risk of relapses, which is important in GPA, and at reducing corticosteroids toxicity.
Mots-clé
Humans, Granulomatosis with Polyangiitis/diagnosis, Granulomatosis with Polyangiitis/therapy, Granulomatosis with Polyangiitis/complications, Antibodies, Antineutrophil Cytoplasmic/therapeutic use, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/therapy, Immunosuppressive Agents/therapeutic use, Adrenal Cortex Hormones/therapeutic use
Pubmed
Création de la notice
11/04/2023 17:14
Dernière modification de la notice
19/07/2023 7:16
Données d'usage